Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
8 hedge funds and large institutions have $31.3M invested in Altamira Therapeutics Ltd in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
20% less funds holding
Funds holding: 10 → 8 (-2)
37% less capital invested
Capital invested by funds: $50M → $31.3M (-$18.7M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.14M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.02M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$712K |
| 4 |
HCM
Harvey Capital Management
Palm Beach,
Florida
|
-$356K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$356K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| – | -$7K | – | – |
|
CYTO Hedge Fund Activity: Q1 2016 in Review
8 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q1 2016, worth a combined $31.3M — down 37% from $50M a quarter earlier.
Fund positioning in CYTO was balanced in Q1 2016: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 3 trimmed.
The largest buyer was Rock Springs Capital Management, opening a new position worth an estimated $3.56M. The largest seller was Tekla Capital Management, cutting an estimated $2.14M.
- 8 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q1 2016, down from 10 in Q4 2015.
- Funds reported $31.3M of Altamira Therapeutics Ltd stock for Q1 2016, down 37% quarter-over-quarter.
- 2 funds opened new Altamira Therapeutics Ltd positions in Q1 2016 and 2 closed out, a net change of 0 holders.
- The largest Altamira Therapeutics Ltd buyer in Q1 2016 was Rock Springs Capital Management, an estimated $3.56M added.
- The largest Altamira Therapeutics Ltd seller in Q1 2016 was Tekla Capital Management, an estimated $2.14M sold.
Based on aggregated 13F filings for Q1 2016.